LG Life Science LTD. Therapeutic and Overview Pipeline Review H2



Wise.Guy.

LG Life Science LTD. Treatment Pipeline Review H2 2016

PUNE, INDIA, November 14, 2016 /EINPresswire.com/ — The report provides comprehensive information on the therapeutics under development by LG Life Science LTD., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/740529-lg-life-science-ltd-product-pipeline-review-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the pipeline therapeutic landscape of LG Life Science LTD.
– The report provides overview of LG Life Science LTD. including its business description, key facts, and locations and subsidiaries
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report assesses LG Life Science LTD.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report features LG Life Science LTD.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
– Evaluate LG Life Science LTD.’s strategic position with total access to detailed information on its product pipeline
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for LG Life Science LTD.
– Identify potential new clients or partners in the target demographic
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding LG Life Science LTD.’s pipeline depth and focus of pipeline therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
LG Life Science LTD. Snapshot 7
LG Life Science LTD. Overview 7
Key Facts 7
LG Life Science LTD. – Research and Development Overview 8
Key Therapeutic Areas 8
LG Life Science LTD. – Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products – Monotherapy 13
Pipeline Products – Combination Treatment Modalities 14
Pipeline Products – Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Pipeline Products – Out-Licensed Products 17
Out-Licensed Products/Combination Treatment Modalities 18
LG Life Science LTD. – Pipeline Products Glance 19
LG Life Science LTD. – Late Stage Pipeline Products 19
Pre-Registration Products/Combination Treatment Modalities 19
Phase III Products/Combination Treatment Modalities 20
LG Life Science LTD. – Clinical Stage Pipeline Products 21
Phase II Products/Combination Treatment Modalities 21
Phase I Products/Combination Treatment Modalities 22
LG Life Science LTD. – Early Stage Pipeline Products 23
Preclinical Products/Combination Treatment Modalities 23
Discovery Products/Combination Treatment Modalities 24
LG Life Science LTD. – Unknown Stage Pipeline Products 25
Unknown Products/Combination Treatment Modalities 25
LG Life Science LTD. – Drug Profiles 26
(gemigliptin + glimepiride) – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
(gemigliptin + metformin hydrochloride) – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
(gemigliptin + rosuvastatin calcium) – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(lercanidipine hydrochloride + valsartan) – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
adalimumab biosimilar – Drug Profile 30
Product Description 30

Access Report @ https://www.wiseguyreports.com/reports/740529-lg-life-science-ltd-product-pipeline-review-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Source: PR